Nuchal translucency and major congenital heart defects in fetuses with normal karyotype: A meta-analysis

Ultrasound in Obstetrics and Gynecology

Volumn 42, Issue 4, 2013, Pages 383-389

  Sotiriadis, A ^a   Papatheodorou, S ^b   Eleftheriades, M ^c   Makrydimas, G ^d  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b CYPRUS UNIVERSITY OF TECHNOLOGY   (Cyprus)

^c EmbryoCare   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cardiac defects; meta analysis; nuchal translucency; screening; ultrasound

Indexed keywords

CONGENITAL HEART MALFORMATION; ECHOGRAPHY; EPIDEMIOLOGY; FETUS DISEASE; HUMAN; KARYOTYPE; META ANALYSIS; NUCHAL TRANSLUCENCY MEASUREMENT; CARDIAC DEFECTS; REVIEW; SCREENING; ULTRASOUND;

EPIDEMIOLOGIC METHODS; FETAL DISEASES; HEART DEFECTS, CONGENITAL; HUMANS; KARYOTYPE; NUCHAL TRANSLUCENCY MEASUREMENT;

CARDIAC DEFECTS; META-ANALYSIS; NUCHAL TRANSLUCENCY; SCREENING; ULTRASOUND;

EID: 84884910569     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.12488     Document Type: Article

References (37)

1. Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH,. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 2005; 192: 1005-1021.
2. Bilardo CM, Timmerman E, Pajkrt E, van Maarle M,. Increased nuchal translucency in euploid fetuses - what should we be telling the parents ? Prenat Diagn 2010; 30: 93-102.
3. Makrydimas G, Sotiriadis A, Ioannidis JP,. Screening performance of first-trimester nuchal translucency for major cardiac defects: a meta-analysis. Am J Obstet Gynecol 2003; 189: 1330-1335.
4. Makrydimas G, Sotiriadis A, Huggon IC, Simpson J, Sharland G, Carvalho JS, Daubeney PE, Ioannidis JP,. Nuchal translucency and fetal cardiac defects: a pooled analysis of major fetal echocardiography centers. Am J Obstet Gynecol 2005; 192: 89-95.
5. Pereira S, Ganapathy R, Syngelaki A, Maiz N, Nicolaides KH,. Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects. Obstet Gynecol 2011; 117: 1384-1391.
6. Bahado-Singh RO, Wapner R, Thom E, Zachary J, Platt L, Mahoney MJ, Johnson A, Silver RK, Pergament E, Filkins K, Hogge WA, Wilson RD, Jackson LG,; First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening Study Group. Elevated first-trimester nuchal translucency increases the risk of congenital heart defects. Am J Obstet Gynecol 2005; 192: 1357-1361.
7. Moses LE, Shapiro D, Littenberg B,. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993; 12: 1293-1316.
8. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
9. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269, W64.
10. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J,. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.
11. Josefsson A, Molander E, Selbing A,. Nuchal translucency as a screening test for chromosomal abnormalities in a routine first trimester ultrasound examination. Acta Obstet Gynecol Scand 1998; 77: 497-499.
12. Bilardo CM, Pajkrt E, de Graaf I, Mol BW, Bleker OP,. Outcome of fetuses with enlarged nuchal translucency and normal karyotype. Ultrasound Obstet Gynecol 1998; 11: 401-406.
13. Mavrides E, Cobian-Sanchez F, Tekay A, Moscoso G, Campbell S, Thilaganathan B, Carvalho JS,. Limitations of using first-trimester nuchal translucency measurement in routine screening for major congenital heart defects. Ultrasound Obstet Gynecol 2001; 17: 106-110.
14. Orvos H, Wayda K, Kozinszky Z, Katona M, Pal A, Szabo J,. Increased nuchal translucency and congenital heart defects in euploid fetuses. The Szeged experience. Eur J Obstet Gynecol Reprod Biol 2002; 101: 124-128.
15. Schwarzler P, Carvalho JS, Senat MV, Masroor T, Campbell S, Ville Y,. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population. Br J Obstet Gynaecol 1999; 106: 1029-1034.
16. Becker R, Schmitz L, Kilavuz S, Stumm M, Wegner RD, Bittner U,. 'Normal' nuchal translucency: a justification to refrain from detailed scan? Analysis of 6858 cases with special reference to ethical aspects. Prenat Diagn 2012; 32: 550-556.
17. Borrell A, Grande M, Bennasar M, Borobio V, Jimenez JM, Stergiotou I, Cuckle H,. First-trimester detection of major cardiac defects with the use of ductus venosus blood flow. Ultrasound Obstet Gynecol 2013; 42: 51-57.
18. Eleftheriades M, Tsapakis E, Sotiriadis A, Manolakos E, Hassiakos D, Botsis D,. Detection of congenital heart defects throughout pregnancy; impact of first trimester ultrasound screening for cardiac abnormalities. J Matern Fetal Neonatal Med 2012; 25: 2546-2550.
19. Volpe P, Ubaldo P, Volpe N, Campobasso G, De Robertis V, Tempesta A, Volpe G, Rembouskos G,. Fetal cardiac evaluation at 11-14 weeks by experienced obstetricians in a low-risk population. Prenat Diagn 2011; 31: 1054-1061.
20. Abu-Rustum RS, Daou L, Abu-Rustum SE,. Role of first-trimester sonography in the diagnosis of aneuploidy and structural fetal anomalies. J Ultrasound Med 2010; 29: 1445-1452.
21. Sananes N, Guigue V, Kohler M, Bouffet N, Cancellier M, Hornecker F, Hunsinger MC, Kohler A, Mager C, Neumann M, Schmerber E, Tanghe M, Nisand I, Favre R,. Nuchal translucency and cystic hygroma colli in screening for fetal major congenital heart defects in a series of 12 910 euploid pregnancies. Ultrasound Obstet Gynecol 2010; 35: 273-279.
22. Timmerman E, Clur SA, Pajkrt E, Bilardo CM,. First-trimester measurement of the ductus venosus pulsatility index and the prediction of congenital heart defects. Ultrasound Obstet Gynecol 2010; 36: 668-675.
23. Lombardi CM, Bellotti M, Fesslova V, Cappellini A,. Fetal echocardiography at the time of the nuchal translucency scan. Ultrasound Obstet Gynecol 2007; 29: 249-257.
24. Muller MA, Clur SA, Timmerman E, Bilardo CM,. Nuchal translucency measurement and congenital heart defects: modest association in low-risk pregnancies. Prenat Diagn 2007; 27: 164-169.
25. Rissanen A, Niemimaa M, Suonpaa M, Ryynanen M, Heinonen S,. First trimester Down's syndrome screening shows high detection rate for trisomy 21, but poor performance in structural abnormalities - regional outcome results. Fetal Diagn Ther 2007; 22: 45-50.
26. Simpson LL, Malone FD, Bianchi DW, Ball RH, Nyberg DA, Comstock CH, Saade G, Eddleman K, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Tripp T, D'Alton ME,. Nuchal translucency and the risk of congenital heart disease. Obstet Gynecol 2007; 109: 376-383.
27. Bruns RF, Moron AF, Murta CG, Goncalves LF, Zamith MM,. The role of nuchal translucency in the screening for congenital heart defects. Arq Bras Cardiol 2006; 87: 307-134.
28. Westin M, Saltvedt S, Bergman G, Kublickas M, Almström H, Grunewald C, Valentin L,. Routine ultrasound examination at 12 or 18 gestational weeks for prenatal detection of major congenital heart malformations? A randomised controlled trial comprising 36,299 fetuses. BJOG 2006; 113: 675-682.
29. Toyama JM, Brizot ML, Liao AW, Lopes LM, Nomura RM, Saldanha FA, Zugaib M,. Ductus venosus blood flow assessment at 11 to 14 weeks of gestation and fetal outcome. Ultrasound Obstet Gynecol 2004; 23: 341-345.
30. Favre R, Cherif Y, Kohler M, Kohler A, Hunsinger MC, Bouffet N, Tanghe M, Cancellier M, Nisand I,. The role of fetal nuchal translucency and ductus venosus Doppler at 11-14 weeks of gestation in the detection of major congenital heart defects. Ultrasound Obstet Gynecol 2003; 21: 239-243.
31. Hafner E, Schuller T, Metzenbauer M, Schuchter K, Philipp K,. Increased nuchal translucency and congenital heart defects in a low-risk population. Prenat Diagn 2003; 23: 985-989.
32. Michailidis GD, Economides DL,. Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses. Ultrasound Obstet Gynecol 2001; 17: 102-105.
33. Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides KH,. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study. BMJ 1999; 318: 81-85.
34. Hyett J, Moscoso G, Papapanagiotou G, Perdu M, Nicolaides KH,. Abnormalities of the heart and great arteries in chromosomally normal fetuses with increased nuchal translucency thickness at 11-13 weeks of gestation. Ultrasound Obstet Gynecol 1996; 7: 245-250.
35. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH,. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008; 31: 376-383.
36. Rutjes AW, Reitsma JB, Di Nisio M, Smidt N, van Rijn JC, Bossuyt PM,. Evidence of bias and variation in diagnostic accuracy studies. CMAJ 2006; 174: 469-476.
37. Papatheodorou SI, Evangelou E, Makrydimas G, Ioannidis JP,. First-trimester ductus venosus screening for cardiac defects: a meta-analysis. BJOG 2011; 118: 1438-1445.